INTRODUCTION
Rather than being a distinct disease, hypertension is an important risk factor for several different cardiovascular conditions, including coronary artery disease (CAD), renal failure and stroke. Despite its global prevalence, there remain many factors that are poorly understood. It is clear that genetic factors have an important role in the development of hypertension, with estimated heritabilities of blood pressure of approximately 20-40%. 1 A number of other factors, including environment and diet, interact with the genome; it may therefore be that examination of the 'downstream' products of genes, in particular proteins and metabolites, will help to improve understanding of the link between environmental and genetic effects in the development of hypertension.
Proteomics is the study of the proteome, the protein complement of the genome. Traditional definitions of disease usually rely on description of the observed symptoms and signs, often without full understanding of the pathophysiology underlying the disease process. For complex conditions such as hypertension or other cardiovascular diseases, the use of single 'markers' to diagnose, stage and assess prognosis is perhaps unrealistic. One advantage of proteomics-based research is that many of these mechanisms can be integrated, developing a 'multimarker' approach. In addition, as proteomics is a 'hypothesis-generating' research tool, it is likely that this line of investigation will open new avenues for potential biomarker discovery, and for new diagnostic and preventative measures.
The human genome contains around 20 000 genes; each gene can be subject to differential splicing, translation and posttranslational modification. As a result, each gene can code for at least 10 times as many proteins, all of which can determine different cellular functions. 2 It can be said, therefore, that while genomics explains one's disposition to disease, proteomics gives a more accurate reflection of proteins expressed and therefore of exact disease processes at the time of study. As the technology becomes more sophisticated and readily available, proteomic analysis has the potential to play a role in clinical practice, in identifying underlying pathophysiological causes of hypertension, in individualising therapy and in detecting early signs of target organ damage.
METHODOLOGY

Sample types
The workflow of proteomic analysis is illustrated in Figure 1 . Proteomic research can be carried out using any type of tissue, bodily fluid or cultured cells. Samples of tissue are the optimal way in which to detect pathological changes, but large-scale studies of human tissue will always be limited by the invasive measures by which they are obtained and by the need to select homogeneous cell populations. In contrast, bodily fluids such as blood plasma, cerebrospinal fluid or urine are more homogeneous, are more easily accessible and hence have all been used for proteomic research.
Polypeptides in all bodily fluids are prone to proteolytic degradation, for example, peptides in human serum have been shown to be exposed to high proteolytic activity immediately upon clotting. 3 Urine may represent a more stable source for proteomic research, as the relative lack of proteolytic activity means that urine peptides are stable enough for accurate analysis. Urine can be stored for several years at À 20 1C, for 3 days at 4 1C or for 6 h at room temperature without significant alterations in the proteome. 4 As a filtrate of blood, urine contains an abundance of information about the functioning of many internal organs, and the appearance in the blood of certain proteins may result in their appearance in the urine, either as intact proteins or as peptide fragments. The peptide composition of the urine, however, depends on a number of factors: glomerular filtration, absorption and secretion in the tubules and lysosomal proteolytic activity at the brush border. 5 Sample preparation One of the key considerations with proteomic research of bodily fluids is sample preparation. The presence of albumin in urine, or lipids in the blood, can cause bias and artefact in proteomic results, and these interfering compounds are therefore normally removed in a standardised protocol. Novel methods for analysis of the serum proteome without prior removal of major blood proteins have recently been introduced and successfully used in proteomic studies of hypertension in pregnancy. 6 Proteomic platforms Two-dimensional gel electrophoresis. Two-dimensional gel electrophoresis (2-DE) separates proteins on two dimensions: their isoelectric point and molecular mass. The proteins are then treated with a proteolytic in-gel digest; the digested protein fragments are extracted and mass spectrometry (MS) is used to analyse the resultant peptide 'fingerprint'. 7 2-DE provides high resolution for high-molecular-weight protein separation and identification. As 2-DE is not an automated process, a potential drawback is that it is too time-consuming for analysis of large numbers of proteins simultaneously and inter-assay comparability is difficult to achieve. The latter point can be improved by 2D-differential gel electrophoresis. The method utilises two samples differentially labelled with two fluorescent dyes. The biological samples are resolved simultaneously within the same gel, with an internal standard comprising equal amounts of all biological samples labelled with a third dye (master gel). The abundance of each protein spot on a gel is determined by its ratio to its corresponding spot of the internal standard in the same gel. 8 Liquid chromatography-MS. Liquid chromatography (LC) is a powerful method of fractionation, which is capable of separating large numbers of analytes on an LC column. Further in-depth analysis provides immense amounts of data and involves multiple separation using different matrices in independent steps (multidimensional protein identification technology). 9 A prerequisite for multidimensional separation is the orthogonality of the individual separation methods, that is, each separation step has to be based on different (orthogonal) molecular properties. The main limitation of LC-MS is the length of time (days) taken for analysis of a single sample. In addition, large proteins (410 kDa) have to be proteolytically cleaved by trypsin before analysis. 2-DE and LC-MS, either independently or together, can therefore analyse proteins with high sensitivity, but neither is suitable for the comparative analysis of large numbers of samples 4 and are mainly limited to biomarker discovery studies, with a subsequent validation of candidate markers by high-throughput platforms, such as enzyme-linked immunosorent assay. Surface-enhanced laser desorption/ionisation-MS. Surface-enhanced laser desorption/ionisation (SELDI) uses different hydrophilic surfaces to adsorb proteins while the unbound proteins are washed away. Binding to the matrix surface separates the proteins making subsequent MS analysis less complex. The purpose of using SELDI is to bind a small but well-defined fraction of proteins to the surface, depending on the pH, concentration and salt content. SELDI has the capacity to analyse multiple samples in a short time, but reproducibility of peptide binding (and therefore subsequent MS analysis) appears to be low. 10 Sample handling, SELDI settings and data analysis therefore have to be strictly controlled. Further, as much of the biological sample is eliminated during preparation, the comparison of data sets analysed with different surfaces or different preparation conditions is limited.
Capillary electrophoresis-MS. Capillary electrophoresis (CE) separates proteins in a single step based on their electrophoretic migration through a buffer-filled capillary. The separated proteins are subsequently detected by a mass spectrometer. CE-MS has the advantage over other techniques that it provides fast separation with high resolution, it uses inexpensive capillaries instead of expensive LC columns and it is compatible with the majority of buffers and analytes.
11 CE-MS enables the generation of comparable high-resolution data sets, allowing the rapid analysis of large numbers of biological samples. Relative quantification using highly abundant, internal, non-marker peptides as references provides similar accuracy compared to stable isotopelabelled peptide standards. 12 As with LC, a drawback of CE is that it is not ideally suited for the analysis of large proteins, which have to be removed with ultrafiltration before CE-MS analysis. 13 Selected reaction monitoring. Selected reaction monitoring is an MS-based technique for analyte quantification.
14 Selected reaction monitoring utilises ion fragmentation in a triple quadrupole mass spectrometer to increase selectivity and allows quantification of proteins across multiple samples even in highly complex mixtures. For selective quantification, the target precursor ion and one of its fragments (transitions) are selected by the first and the third quadrupole and monitored over time. The second quadrupole provides collision fragmentation, and co-eluting background ions are filtered out. In contrast to other MS-based proteomic techniques, only narrow mass windows rather than full mass spectra are recorded. Label-free relative quantification can be performed based on the absolute signal intensity of the individual samples. Alternatively, quantification can also be based on the relative intensities of the sample analytes compared to an internal standard labelled with stable isotopes.
Selected reaction monitoring combines high analyte selectivity with low limits of detection and high throughput. The synchronous analysis of multiple analytes, however, remains technically challenging. 15 Protein microarrays. Protein microarrays detect specific proteins in a non-MS-based approach. The 'targeted' approach prints specific antibodies or antigens onto support membrane material for quantification of multiple proteins via immunohistochemistry.
After hybridisation to the array, the analytes are detected by the immobilised antigens or antibodies. The demand to detect extremely low-abundance proteins in complex mixtures has resulted in the development of sensitive, real-time and multiplexed detection platforms using fluorescence, chemiluminescence or radioactive isotopes, as well as more recent advancements, including quantum dots, gold nanoparticles or dye-doped nanoparticles. 16 Although the approach has recently found an increasing number of applications, the requirement for a highly specific probe for every analyte restricts the ability to rapidly and efficiently study thousands of proteins simultaneously.
Proteomic studies in animal models Experimental work from Thongboonkersd et al. 17 examined the renal proteome in rats exposed to hypoxia, which was either episodic or sustained. Episodic hypoxia is a feature of obstructive sleep apnoea, a condition associated with systemic hypertension. Animals exposed to intermittent hypoxia had changes in 2-DE renal protein expression indicative of impaired vasodilatation and vascular hypertrophy. In contrast, the proteome of animals exposed to sustained hypoxia demonstrated features consistent with compensatory vasodilatation and vascular remodelling, helping to prevent the development of hypertension. This study illustrates the use of proteomics to unravel the pathophysiology of specific forms of hypertension under well-controlled conditions.
Jin et al. 18 used 2D CE-MS to study protein expression in left ventricular myocardium in spontaneously hypertensive and control Wistar Kyoto rats to study left ventricular hypertrophy. They reported 13 proteins that were differentially expressed in the spontaneously hypertensive animals before the onset of hypertension. These proteins included a-enolase and lactate dehydrogenase B, two important enzymes for glycolysis, as well as proteins known to be associated with mitochondrial oxidant phosphorylation, oxidative stress and cellular energy metabolism. Lee et al. 19 reported the use of 2D CE-MS to study protein expression profiles in aortic smooth muscle. They reported seven proteins that were differentially expressed between spontaneously hypertensive and Wistar Kyoto animals, including reduced expression of dihydropteridine reductase (DHPR), which is associated with the regeneration of tetra-hydrobiopterin (BH4) and is involved in the development of vascular oxidative stress. Delbosc et al. 20 administered low-dose nitro-L-arginine, a blocker of nitric oxide, as a model of hypertension in Fischer and Brown Norway rat strains. Fischer rats were more susceptible to development of hypertension than Brown Norway rats in response to nitro-L-arginine administration. Examination of the proteome from the aorta in affected animals revealed differential expression of four peptides: ubiquitin, SMS22a, thymosin b-4 and the C-terminal fragment of filamin A.
There is a huge potential to use proteomic strategies to study downstream effects of specific manipulations or in specific models. These studies are examples, but further potential lies in studies of genetically manipulated models 21 or congenic models, 22 where a limited number of genes are responsible for changes in the phenotype, and dissection of the proteome may be less complex.
Human studies in hypertension-associated conditions Ageing. Hypertension becomes more common with increasing age, and insight into the effects of ageing on the vasculature can be gained from examining the proteome. To further examine this, Zü rbig et al. 23 examined urine from 324 healthy individuals by CE-MS whose ages ranged from 2 to 72 years. Significant age-related peptide changes occurred with 325 of the 5000 urinary peptides examined. There was significant overlap between peptides associated with ageing and those associated with various forms of chronic renal disease. These findings led us to suggest that modification of proteolytic activity and reduced turnover of extracellular matrix can be associated with the vascular effects of ageing. Further work has demonstrated that telomere dysfunction, which limits the proliferative capacity of cells and is associated with normal human ageing and with chronic disease, can be detected using proteomic studies in bone marrow cell culture supernatant of telomerase knockout mice. 24 Coronary artery disease. Using CE-MS technology, Zimmerli et al. 25 reported a set of 15 urine peptides that defined a characteristic CAD signature panel, which had a sensitivity of 98% and a specificity of 83%. This study used patients with severe CAD Proteomics in hypertension DM Carty et al on coronary angiography, comparing them with apparently healthy controls. In a further study by von zur Mü hlen et al., 26 which reflected the 'real-life' situation faced by clinicians, urine and plasma proteomics of patients with acute chest pain and cardiovascular risk factors were examined; all patients subsequently underwent coronary angiography to confirm or exclude significant CAD. Using a combination of 17 peptides, we reported a sensitivity of 81% and a specificity of 92% for diagnosing CAD. The majority of urinary peptides associated with CAD identified in these studies originated from collagen, reflecting its central role in the pathophysiology of atherosclerosis. Plasma proteomics did not accurately discriminate between patients with CAD and those without, perhaps related to latent protease activity in the plasma. 3 Renal disease. Identification of patients with chronic kidney disease at an early disease stage and early diagnosis of specific kidney diseases without requirement for renal biopsy is a further area of clinical research addressed by proteome analyses. Urinary proteomics is particularly suitable for detection of renal disease. Of the 150 mg per day of protein excreted by healthy individuals, 70% of the constituent proteins are derived from the kidney and 30% from the plasma. 27 To date, urinary proteomic studies have determined disease-specific urine peptide patterns for IgAassociated nephropathy, ureteropelvic junction obstruction lupus nephritis and anti-neutrophil cytoplasmic antibody-associated vasculitis. 28 Peptide patterns specific to diabetic nephropathy have also been described, which can predict the development of diabetic nephropathy before microalbuminuria can be detected. 28 Stroke. Although imaging with CT scanning and related modalities is the mainstay of investigation in patients with suspected stroke, the identification of accurate biomarkers for stroke could be of benefit in centres with limited access to neuroimaging, in identification of small infarcts that do not show up on imaging and in differentiation from other pathologies including migraine.
In keeping with studies of hypertension, however, proteomic studies in cerebrovascular disease have been largely restricted to animal models, including the stroke-prone spontaneously hypertensive rat. 29 One human study was reported by Cuadrado et al., 30 in which specimens from cadaveric brains from six patients with total anterior circulation stroke and documented middle cerebral artery occlusion were compared with three controls who had died from non-neurological causes. Differential gel electrophoresis was used to examine differential protein expression. Levels of proteins involved in metabolism and biosynthesis were reduced in infarct core samples, while in infarcted areas there were higher levels of fibrinogen, albumin and proteins involved in the immune response such as markers of complement activation. Although clearly the post-mortem changes may have altered protein expression, these and other studies may help to identify novel pathways for the development of biomarkers and therapeutic targets.
Montaner et al. 31 examined a panel of 12 plasma biomarkers, of which S100 calcium binding protein (S100B) and soluble receptor for advanced glycation end products accurately differentiated between ischaemic and haemorrhagic stroke. Dayon et al. 32 examined brain extracellular fluid in patients with malignant middle cerebral artery infarcts. The authors used cerebral microdialysis catheters to obtain the fluid and 1D gel electrophoresis/matrix-assisted laser desorption/ionisation-time of flight MS to identify differences in proteins expressed in the infarct core, the penumbra and the contralateral side of the brain. Differences in expression of 53 different proteins were seen in the infarct core and penumbra compared to the contralateral brain, including glial fibrillary acidic protein, myelin basic protein and S100B, all biomarkers that have been previously reported in the context of acute stroke.
Proteomic studies in pre-eclampsia Pre-eclampsia-and pregnancy-induced hypertension are specific forms of hypertension that share a number of features with essential hypertension. 33 The disease is thought to be caused by a complex interaction between inflammation, oxidative stress and other as yet unknown factors in the developing placenta, and an inappropriate maternal response characterised by endothelial dysfunction. 34 Although blood pressure returns to normal after delivery in affected women, the condition shares a number of risk factors and pathophysiological mechanisms with hypertension. Further, women who suffer from pre-eclampsia are at increased risk of going on to develop hypertension, cardiac disease and stroke in later life. 33 As renal pathology is one of the hallmarks of pre-eclampsia, it may be that proteomic analysis of the urine will help point to novel pathophysiological mechanisms. One such study reported the use of urinary proteomics in pre-eclampsia. Buhimschi et al. 35 studied urine from 284 women, of whom 88 had developed preeclampsia. Urine samples were taken at the time of disease onset; proteomic profiles for pre-eclampsia were generated using SELDI, and peptides were then identified using tandem MS. The proteomic profile for pre-eclampsia was then validated in a separate cohort of 225 pregnant women, and was compared with other markers of disease severity including albumin: creatinine ratio. The proteomic signature profile for preeclampsia was largely characterised by fragments of serpin peptidase inhibitor (SERPINA) 1 and albumin. SERPINA1 is an abundant plasma protein, which has a role in the inhibition of neutrophil elastase, trypsin and pancreatic elastase. This work therefore demonstrated that a urine proteomic 'fingerprint' made up of SERPINA1 and albumin fragments can diagnose pre-eclampsia, and can differentiate severe forms of the disease from milder variants.
We recently reported a study that was designed to identify peptide biomarker patterns to predict pre-eclampsia before the onset of clinically detectable disease. 36 By comparing healthy pregnant women with healthy non-pregnant women, we were able to determine a CE-MS urinary peptide pattern of 284 proteins that were altered in normal pregnancy. In a subsequent step, we used these peptides to compare women who developed preeclampsia with those who had normotensive pregnancies, and were able to determine a biomarker pattern made up of 50 peptides that accurately predicts pre-eclampsia at 28 weeks of gestation, well before the onset of hypertension and proteinuria that characterise the condition. We were unable to detect such peptide patterns in the first trimester of pregnancy. It was of interest that the peptides detected in the urine of pre-eclamptic women were characterised by fibrinogen, collagen fragments and uromodulin, indicating the key role of the endothelium in disease development.
One study in which maternal serum was used to examine the proteome in women affected by pre-eclampsia was reported by Watanabe et al. 37 2-DE was used to examine maternal serum from six patients with established pre-eclampsia associated with foetal growth restriction, and six matched women with normal pregnancies. Overexpressed spots on 2-DE were then identified using matrix-assisted laser desorption/ionisation-time of flight MS and western blot analysis. Using these techniques, pre-eclamptic women were found to overexpress clusterin, a protein that induces cholesterol efflux from lipid-laden macrophages and is associated with vascular disease, renal disease and oxidative stress. These findings were then validated in a separate cohort of 80 pre-eclamptic women.
Further proteomic studies have been performed on plasma. One study using 2-DE techniques for protein separation was reported by Wang et al., 38 who examined plasma in 11 women with pre-eclampsia and 11 normotensive controls. Using MS to identify peptides, they were able to demonstrate a significant reduction in pre-eclamptic women in H-ficolin and L-ficolin, factors thought to play a role in innate immunity. A more recent study used 2D-differential gel electrophoresis to examine the plasma proteome at 20 weeks' gestation in a cohort of 27 women who went on to develop pre-eclampsia with appropriately grown babies, 12 who developed pre-eclampsia in association with foetal growth restriction and 57 controls who had normal pregnancies. 39 After trypsination, protein spots of interest were then identified using LC-MS. The authors found that 36 moderate-to-highabundance proteins were differentially expressed in preeclamptic women at 20 weeks before the onset of clinical disease.
Limitations and outlook One potential limitation to proteomic technologies is that the full effect on the proteome of factors such as ageing, disease, gender and ethnicity are not yet fully understood. However, it becomes evident that proteomics can be applied in specific conditions such as chronic kidney disease. More detailed studies in experimental models in parallel to human studies are required not only to gain further insight but also to develop and refine analysis methods. Appropriate samples reflecting the entire spectrum of clinically relevant conditions are necessary to develop novel proteomic approaches suitable for routine clinical applications. In our studies, we have calibrated findings using a panel of 'housekeeping' peptides that appear to be unaffected by such factors, 12 but these may not be transferable to other technological approaches. In addition, common standards that enable integration of data from proteomic technologies are essential to take advantage of the full potential of the techniques given the intrinsic biological variability of the human proteome.
At present, integration of biomarker information developed from the various proteomic strategies remains a challenge, and improvements in analysis and modelling will be required before different strategies can be compared or combined. It is expected that the different approaches will be complementary to each other, as well as to other approaches such as genomics and metabolomics. As with genomic studies, proteomic studies will have to follow strict rules to avoid generating false (positive or negative) results. A further important challenge of proteomic studies is the subsequent implementation in clinical routine. A recently suggested roadmap towards clinical implementation 40 holds the promise that we may soon see proteomics in clinical medicine.
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